Form 4: Dexcom Director Kyle Malady Reports Stock Award and Disposal

Director Kyle Malady reports acquisition of 5,192 shares of Dexcom stock via restricted stock units (RSUs) and disposal of 23,334 shares.

Summary

• On May 8, 2025, Kyle Malady, a director of Dexcom Inc., reported a transaction involving Dexcom's common stock.
• Malady acquired 5,192 shares through a restricted stock unit (RSU) award.
• The RSU award vests on the earlier of one year from the grant date or Dexcom's 2026 Annual Meeting of Stockholders.
• Malady also disposed of 23,334 shares.
• Following these transactions, Malady beneficially owns 23,334 shares of Dexcom common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders (directors, officers, and 10% owners) of publicly traded companies, providing transparency into their transactions in the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• It allows investors to monitor the actions of company directors.

Key Dates

Keywords

Dexcom, DXCM, Form 4, Director, Kyle Malady, Stock, RSU, Restricted Stock Units, Beneficial Ownership, Transaction